AKTX logo

AKTX
Akari Therapeutics

9,311
Mkt Cap
$232.68M
Volume
32.11M
52W High
$56.80
52W Low
$3.02
PE Ratio
-0.02
AKTX Fundamentals
Price
$18.27
Prev Close
$5.14
Open
$9.92
50D MA
$5.30
Beta
0.72
Avg. Volume
66,344.47
P/B
0.41
Rev/Employee
$0.00
$384.65
Loading...
Loading...
News
all
press releases
Akari Therapeutics Stock Jumps On Promising Preclinical Data
Akari Therapeutics shares are surging after preclinical data showed AKTX101 synergized with KRAS inhibition in pancreatic cancer models.read more...
News Placeholder
More News
News Placeholder
This Emerging Biotech Wave Could Create the Next Monster Healthcare Winners
The biotechnology sector continues attracting speculative capital as investors aggressively position around next-generation oncology, metabolic disease, and CNS therapy platforms. Artificial intelligence, precision medicine, RNA biology, and novel drug delivery technologies are rapidly reshaping how Wall Street evaluates emerging healthcare companies. As larger pharmaceutical companies race to secure pipeline assets and differentiated platforms, smaller clinical-stage companies with compelling preclinical or clinical data are increasingly finding themselves under the spotlight. $AKTX, $NTHI, $MTVA, $HCWB, $BAC, $STT, $BCS
News Placeholder
AKTX Stock Goes Parabolic After Hours On $5.5M Capital Raise, Cancer Data Win: Wall Street Sees 400% Upside
Akari said its experimental therapy AKTX-101 showed strong results when paired with an already-approved cancer drug in lab tests on pancreatic cancer cells that carry a common KRAS mutation.
News Placeholder
The Biotech Repricing Wave May Be Starting as Capital Pours into High-Impact Oncology Platforms
Biotech investors are once again rotating aggressively into clinical-stage growth stories as a fresh wave of capital raises, pipeline expansions, analyst initiations, and oncology breakthroughs reshapes momentum across the sector. $NTHI, $IMMX, $RLAY, $AKTX, $LIMN
News Placeholder
Why Akari Therapeutics Stock Is Surging On Thursday?
Akari Therapeutics PLC (NASDAQ:AKTX) sees stock growth fueled by Q1 2026 earnings optimism and a new European patent for its PH1 ADC payload.read more...
<
...
1
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available